Review of Treatments for ADPKD on Tolvaptan and ketogenic Dietary Intervention as a Novel Therapy

Research Article
Open access

Review of Treatments for ADPKD on Tolvaptan and ketogenic Dietary Intervention as a Novel Therapy

Qiaoyu Shen 1*
  • 1 University of California, Santa Barbara    
  • *corresponding author qiaoyushen@ucsb.edu
Published on 28 April 2023 | https://doi.org/10.54254/2753-8818/3/20220214
TNS Vol.3
ISSN (Print): 2753-8826
ISSN (Online): 2753-8818
ISBN (Print): 978-1-915371-25-6
ISBN (Online): 978-1-915371-26-3

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), the most prevalent genetic kidney disease, affected millions of individuals worldwide. And it is also one of the most prevalent causes of kidney failures and transplants. Previously, in many years, mitigating its symptoms had been the only treatment for this disease. After more than a decade after the early clinical studies of medicines for ADPKD began, the first medication that may successfully delay the course of the condition is now on the market. Due to the severe side effects and high cost of tolvaptan, it cannot be considered a full success, but rather the beginning of therapeutic research. More recently, enlightened by the discovery of the defective metabolism of PKD related cells, researchers have been designing dietary plans and new lifestyles for ADPKD patients to slow down or even halt the disease progression. Current outcomes have been promising. This article will address the best practices for treating ADPKD patients, with a focus on medications that have been proved to be beneficial in preserving kidney’s function and structure.

Keywords:

treatment, tolvaptan, ketogenic diet, autosomal dominant polycystic kidney disease, metabolism

Shen,Q. (2023). Review of Treatments for ADPKD on Tolvaptan and ketogenic Dietary Intervention as a Novel Therapy. Theoretical and Natural Science,3,150-154.
Export citation

References

[1]. M.B. Lanktree, A. Haghighi, E. Guiard, I.-A. Iliuta, X. Song, P.C. Harris, A.D. Paterson, and Y. Pei, Journal of the American Society of Nephrology 29, 2593 (2018)

[2]. S. Strubl, S. Oehm, J.A. Torres, F. Grundmann, J. Haratani, M. Decker, S. Vuong, A. Kaur Bhandal, N. Methot, R. Haynie-Cion, F. Meyer, F. Siedek, U. Korst, R.-U. Mü, and T. Weimbs, Clinical Kidney Journal (2021).

[3]. A.S.L. Yu, C. Shen, D.P. Landsittel, J.J. Grantham, L.T. Cook, V.E. Torres, A.B. Chapman, K.T. Bae, M. Mrug, P.C. Harris, F.F. Rahbari-Oskoui, T. Shi, and W.M. Bennett, Kidney International 95, 1253 (2019).

[4]. V.E. Torres, A.B. Chapman, O. Devuyst, R.T. Gansevoort, J.J. Grantham, E. Higashihara, R.D. Perrone, H.B. Krasa, J. Ouyang, and F.S. Czerwiec, New England Journal of Medicine 367, 2407 (2012).

[5]. V.E. Torres, A.B. Chapman, O. Devuyst, R.T. Gansevoort, R.D. Perrone, G. Koch, J. Ouyang, R.D. McQuade, J.D. Blais, F.S. Czerwiec, and O. Sergeyeva, New England Journal of Medicine 377, 1930 (2017).

[6]. L.F. Menezes, C.-C. Lin, F. Zhou, and G.G. Germino, EBioMedicine 5, 183 (2016).

[7]. R.-U. Müller and T. Benzing, Clinical Kidney Journal 11, 2 (2018).

[8]. J.A. Torres, M. Rezaei, C. Broderick, L. Lin, X. Wang, B. Hoppe, B.D. Cowley, V. Savica, V.E. Torres, S. Khan, R.P. Holmes, M. Mrug, and T. Weimbs, Journal of Clinical Investigation 129, 4506 (2019).

[9]. D.M. Bruen, J.J. Kingaard, M. Munits, C.S. Paimanta, J.A. Torres, J. Saville, and T. Weimbs, Kidney and Dialysis 2, 183 (2022).

[10]. M. Bargagli, N.A. Dhayat, M. Anderegg, M. Semmo, U. Huynh-Do, B. Vogt, P.M. Ferraro, and D.G. Fuster, Clinical Journal of the American Society of Nephrology 15, 1007 (2020).

[11]. T.R. Tidwell, K. Søreide, and H.R. Hagland, Aging and Disease 8, 662 (2017).

[12]. B. Reed, I. Helal, K. McFann, W. Wang, X.-D. Yan, and R.W. Schrier, Nephrology Dialysis Transplantation 27, 2862 (2011).

[13]. K.L. Nowak and K. Hopp, Clinical Journal of the American Society of Nephrology 15, 577 (2020).

Cite this article

Shen,Q. (2023). Review of Treatments for ADPKD on Tolvaptan and ketogenic Dietary Intervention as a Novel Therapy. Theoretical and Natural Science,3,150-154.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part I

ISBN：978-1-915371-25-6(Print) / 978-1-915371-26-3(Online)
Editor：Gary Royle, Steven M. Lipkin
Conference website: http://www.icbiomed.org
Conference date: 7 November 2022
Series: Theoretical and Natural Science
Volume number: Vol.3
ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).

References

[1]. M.B. Lanktree, A. Haghighi, E. Guiard, I.-A. Iliuta, X. Song, P.C. Harris, A.D. Paterson, and Y. Pei, Journal of the American Society of Nephrology 29, 2593 (2018)

[2]. S. Strubl, S. Oehm, J.A. Torres, F. Grundmann, J. Haratani, M. Decker, S. Vuong, A. Kaur Bhandal, N. Methot, R. Haynie-Cion, F. Meyer, F. Siedek, U. Korst, R.-U. Mü, and T. Weimbs, Clinical Kidney Journal (2021).

[3]. A.S.L. Yu, C. Shen, D.P. Landsittel, J.J. Grantham, L.T. Cook, V.E. Torres, A.B. Chapman, K.T. Bae, M. Mrug, P.C. Harris, F.F. Rahbari-Oskoui, T. Shi, and W.M. Bennett, Kidney International 95, 1253 (2019).

[4]. V.E. Torres, A.B. Chapman, O. Devuyst, R.T. Gansevoort, J.J. Grantham, E. Higashihara, R.D. Perrone, H.B. Krasa, J. Ouyang, and F.S. Czerwiec, New England Journal of Medicine 367, 2407 (2012).

[5]. V.E. Torres, A.B. Chapman, O. Devuyst, R.T. Gansevoort, R.D. Perrone, G. Koch, J. Ouyang, R.D. McQuade, J.D. Blais, F.S. Czerwiec, and O. Sergeyeva, New England Journal of Medicine 377, 1930 (2017).

[6]. L.F. Menezes, C.-C. Lin, F. Zhou, and G.G. Germino, EBioMedicine 5, 183 (2016).

[7]. R.-U. Müller and T. Benzing, Clinical Kidney Journal 11, 2 (2018).

[8]. J.A. Torres, M. Rezaei, C. Broderick, L. Lin, X. Wang, B. Hoppe, B.D. Cowley, V. Savica, V.E. Torres, S. Khan, R.P. Holmes, M. Mrug, and T. Weimbs, Journal of Clinical Investigation 129, 4506 (2019).

[9]. D.M. Bruen, J.J. Kingaard, M. Munits, C.S. Paimanta, J.A. Torres, J. Saville, and T. Weimbs, Kidney and Dialysis 2, 183 (2022).

[10]. M. Bargagli, N.A. Dhayat, M. Anderegg, M. Semmo, U. Huynh-Do, B. Vogt, P.M. Ferraro, and D.G. Fuster, Clinical Journal of the American Society of Nephrology 15, 1007 (2020).

[11]. T.R. Tidwell, K. Søreide, and H.R. Hagland, Aging and Disease 8, 662 (2017).

[12]. B. Reed, I. Helal, K. McFann, W. Wang, X.-D. Yan, and R.W. Schrier, Nephrology Dialysis Transplantation 27, 2862 (2011).

[13]. K.L. Nowak and K. Hopp, Clinical Journal of the American Society of Nephrology 15, 577 (2020).

For authors
Guide for authors Policies for authors Aims and scope Subscription Open access policy
For editors
Policies for editors Editorial board
For reviewers
Policies for reviewers Privacy policy

Cookies are used by this site.
Copyright © 2024 EWA Publishing, its licensors, and contributors. All rights reserved, including text and data mining, AI training, and similar technologies.